Search

Your search keyword '"Arima, Nobuyoshi"' showing total 44 results
Start Over Author "Arima, Nobuyoshi" Search Limiters Full Text
44 results on '"Arima, Nobuyoshi"'

1. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

Author

Nakamura, Naokazu, Arima, Nobuyoshi, Takakuwa, Teruhito, Yoshioka, Satoshi, Imada, Kazunori, Fukushima, Kentaro, Hotta, Masaaki, Fuchida, Shin-ichi, Kanda, Junya, Uoshima, Nobuhiko, Shimura, Yuji, Tanaka, Hirokazu, Ohta, Kensuke, Kosugi, Satoru, Yagi, Hideo, Yoshihara, Satoshi, Yamamura, Ryosuke, Adachi, Yoko, Hanamoto, Hitoshi, Shibayama, Hirohiko, Hosen, Naoki, Ito, Tomoki, Shimazaki, Chihiro, Takaori-Kondo, Akifumi, Kuroda, Junya, Matsumura, Itaru, and Hino, Masayuki

Published
2024
Full Text
View/download PDF

2. Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan

Author

Iemura, Tomoki, Kondo, Tadakazu, Ueda, Atsushi, Maeda, Takeshi, Kitawaki, Toshio, Arai, Yasuyuki, Kanda, Junya, Ikeda, Takashi, Imada, Kazunori, Ishikawa, Takayuki, Anzai, Naoyuki, Itoh, Mitsuru, Takeoka, Tomoharu, Akasaka, Takashi, Yago, Kazuhiro, Yonezawa, Akihito, Arima, Nobuyoshi, Kitano, Toshiyuki, Nohgawa, Masaharu, Watanabe, Mitsumasa, Moriguchi, Toshinori, Yamashita, Kouhei, Ueda, Yasunori, Matsumoto, Kana, and Takaori-Kondo, Akifumi

Published
2023
Full Text
View/download PDF

4. Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning

Author

Iwasaki, Makoto, Kanda, Junya, Arai, Yasuyuki, Kondo, Tadakazu, Ishikawa, Takayuki, Ueda, Yasunori, Imada, Kazunori, Akasaka, Takashi, Yonezawa, Akihito, Yago, Kazuhiro, Nohgawa, Masaharu, Anzai, Naoyuki, Moriguchi, Toshinori, Kitano, Toshiyuki, Itoh, Mitsuru, Arima, Nobuyoshi, Takeoka, Tomoharu, Watanabe, Mitsumasa, Hirata, Hirokazu, Asagoe, Kosuke, Miyatsuka, Isao, An, Le My, Miyanishi, Masanori, and Takaori-Kondo, Akifumi

Published
2022
Full Text
View/download PDF

6. Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group

Author

Watanabe, Mizuki, Kanda, Junya, Arai, Yasuyuki, Hishizawa, Masakatsu, Nishikori, Momoko, Ishikawa, Takayuki, Imada, Kazunori, Ueda, Yasunori, Akasaka, Takashi, Yonezawa, Akihito, Nohgawa, Masaharu, Kitano, Toshiyuki, Itoh, Mitsuru, Takeoka, Tomoharu, Moriguchi, Toshinori, Yago, Kazuhiro, Arima, Nobuyoshi, Anzai, Naoyuki, Watanabe, Mitsumasa, Kondo, Tadakazu, and Takaori-Kondo, Akifumi

Published
2020
Full Text
View/download PDF

7. Increased Relapse Risk of Acute Lymphoid Leukemia in Homozygous HLA-C1 Patients after HLA-Matched Allogeneic Transplantation: A Japanese National Registry Study

Author

Arima, Nobuyoshi, Kanda, Junya, Yabe, Toshio, Morishima, Yasuo, Tanaka, Junji, Kako, Shinichi, Sakaguchi, Hirotoshi, Kato, Motohiro, Ohashi, Kazuteru, Ozawa, Yukiyasu, Fukuda, Takahiro, Ota, Shuichi, Tachibana, Takayoshi, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Kanda, Yoshinobu

Published
2020
Full Text
View/download PDF

8. Impact of Homozygous Conserved Extended HLA Haplotype on Single Cord Blood Transplantation: Lessons for Induced Pluripotent Stem Cell Banking and Transplantation in Allogeneic Settings

Author

Morishima, Yasuo, Morishima, Satoko, Murata, Makoto, Arima, Nobuyoshi, Uchida, Naoyuki, Sugio, Yasuhiro, Takahashi, Satoshi, Matsuhashi, Yoshiko, Onizuka, Makoto, Eto, Tetsuya, Nagafuji, Koji, Onishi, Yasushi, Inoue, Masami, Atsuta, Yoshiko, Fukuda, Takahiro, Ichinohe, Tatsuo, Kato, Shunichi, and Kanda, Junya

Published
2020
Full Text
View/download PDF

9. Epitope Mismatch at HLA-DRB1 Associates with Reduced Relapse Risk in Cord Blood Transplantation for Standard-Risk Hematologic Malignancy

Author

Morita-Fujita, Mari, Shindo, Takero, Iemura, Tomoki, Arai, Yasuyuki, Kanda, Junya, Okada, Kazuya, Ueda, Yasunori, Yoshiyuki, Onda, Anzai, Naoyuki, Mori, Takuto, Ishikawa, Takayuki, Otsuka, Yasuyuki, Yonezawa, Akihito, Yuhi, Naoki, Imada, Kazunori, Oba, Akifumi, Itoh, Mitsuru, Okamoto, Yoshio, Kitano, Toshiyuki, Ikeda, Takashi, Kotani, Shinichi, Akasaka, Takashi, Yago, Kazuhiro, Watanabe, Mitsumasa, Nohgawa, Masaharu, Tsuji, Masaaki, Takeoka, Tomoharu, Yamamoto, Ryusuke, Arima, Nobuyoshi, Yoshinaga, Noriyoshi, Hishizawa, Masakatsu, Yamashita, Kouhei, Kondo, Tadakazu, and Takaori-Kondo, Akifumi

Published
2023
Full Text
View/download PDF

12. Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia

Author

Arima, Nobuyoshi, Kanda, Junya, Tanaka, Junji, Yabe, Toshio, Morishima, Yasuo, Kim, Sung-Won, Najima, Yuho, Ozawa, Yukiyasu, Eto, Tetsuya, Kanamori, Heiwa, Mori, Takehiko, Kobayashi, Naoki, Kondo, Tadakazu, Nakamae, Hirohisa, Uchida, Naoyuki, Inoue, Masami, Fukuda, Takahiro, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Kanda, Yoshinobu

Published
2018
Full Text
View/download PDF

13. Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study

Author

Arima, Nobuyoshi, Nakamura, Fumiaki, Yabe, Toshio, Tanaka, Junji, Fuji, Shigeo, Ohashi, Kazuteru, Fukuda, Takahiro, Miyamura, Koichi, Iwato, Koji, Eto, Tetsuya, Mori, Takehiko, Kobayashi, Naoki, Hoshino, Takumi, Kato, Chiaki, Kanamori, Heiwa, Nakamae, Hirohisa, Atsuta, Yoshiko, Morishima, Yasuo, and Kanda, Yoshinobu

Published
2016
Full Text
View/download PDF

14. Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies

Author

Wada, Fumiya, Kanda, Junya, Yoshioka, Satoshi, Ishikawa, Takayuki, Akasaka, Takashi, Ueda, Yasunori, Hirata, Hirokazu, Arai, Yasuyuki, Yago, Kazuhiro, Anzai, Naoyuki, Watanabe, Mitsumasa, Ikeda, Takashi, Yonezawa, Akihito, Imada, Kazunori, Itoh, Mitsuru, Kitano, Toshiyuki, Takeoka, Tomoharu, Hishizawa, Masakatsu, Nohgawa, Masaharu, Arima, Nobuyoshi, Asagoe, Kousuke, Kondo, Tadakazu, and Takaori-Kondo, Akifumi

Subjects
Transplantation, endocrine system, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, fluids and secretions, Recurrence, Hematologic Neoplasms, embryonic structures, Humans, Cord Blood Stem Cell Transplantation, Unrelated Donors, Cyclophosphamide, Retrospective Studies
Abstract

[Background.] Unrelated cord blood (UCB) and haploidentical related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) have become alternative options to treat patients with hematological malignancies without a HLA-matched donor. [Methods.] We conducted a retrospective study using registry data from the Kyoto Stem Cell Transplantation Group for patients with hematological malignancies who received their first allogeneic hematopoietic cell transplantation using a single UCB unit (n = 460) or PTCy-haplo (N = 57) between 2013 and 2019. [Results.] We found that overall survival in the UCB group was comparable to that in the PTCy-haplo group (hazard ratio, 1.00; 95% confidence interval, 0.66-1.52), although neutrophil and platelet engraftment were significantly delayed. Nonrelapse mortality risk and the incidence of graft-versus-host disease in the UCB group were also comparable to those in the PTCy-haplo group. Although the relapse risk was similar between the UCB group and the PTCy-haplo group regardless of the disease risk, acute myeloid leukemia patients benefit from UCB transplant with a significantly lower relapse rate (hazard ratio, 0.38; 95% confidence interval, 0.18-0.76). [Conclusions.] UCB transplant gives outcomes comparable to PTCy-haplo transplant, and both UCB and PTCy-haplo units are suitable as alternative donor sources for patients without an HLA-matched sibling or unrelated donor.

Published
2022

15. Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation

Author

30636311, 10826564, Wada, Fumiya, Kanda, Junya, Kamijo, Kimimori, Nishikubo, Masashi, Yoshioka, Satoshi, Ishikawa, Takayuki, Ueda, Yasunori, Akasaka, Takashi, Arai, Yasuyuki, Izumi, Kiyotaka, Hirata, Hirokazu, Ikeda, Takashi, Yonezawa, Akihito, Anzai, Naoyuki, Watanabe, Mitsumasa, Imada, Kazunori, Yago, Kazuhiro, Tamura, Naoki, Itoh, Mitsuru, Masuo, Yuki, Kunitomi, Akane, Takeoka, Tomoharu, Kitano, Toshiyuki, Arima, Nobuyoshi, Hishizawa, Masakatsu, Asagoe, Kohsuke, Kondo, Tadakazu, Takaori-Kondo, Akifumi, 30636311, 10826564, Wada, Fumiya, Kanda, Junya, Kamijo, Kimimori, Nishikubo, Masashi, Yoshioka, Satoshi, Ishikawa, Takayuki, Ueda, Yasunori, Akasaka, Takashi, Arai, Yasuyuki, Izumi, Kiyotaka, Hirata, Hirokazu, Ikeda, Takashi, Yonezawa, Akihito, Anzai, Naoyuki, Watanabe, Mitsumasa, Imada, Kazunori, Yago, Kazuhiro, Tamura, Naoki, Itoh, Mitsuru, Masuo, Yuki, Kunitomi, Akane, Takeoka, Tomoharu, Kitano, Toshiyuki, Arima, Nobuyoshi, Hishizawa, Masakatsu, Asagoe, Kohsuke, Kondo, Tadakazu, and Takaori-Kondo, Akifumi

Abstract

Haploidentical-related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) and cord blood transplantation (CBT) are valid alternatives for patients with hematological malignancies when HLA-matched donor transplantation (MDT) is unavailable. However, the effects of graft-versus-host disease (GVHD) on outcomes after these transplants have not been fully elucidated. Therefore, we evaluated the effects of acute and chronic GVHD on transplant outcomes after PTCy-haplo transplants and compared them with CBT and MDT. We included a total of 914 adult patients with hematological malignancies in the Kyoto Stem Cell Transplantation Group registry who received PTCy-haplo (N = 120), CBT (N = 402), and MDT (N = 392), and achieved neutrophil engraftment. A multivariate analysis revealed that grade I-II acute GVHD improved of overall survival (OS) after PTCy-haplo [hazard ratio (HR) = 0.39, P = 0.018] and CBT (HR = 0.48, P < 0.001), but not after MDT (HR = 0.80, P = 0.267) compared with patients without acute GVHD. Grade I-II acute GVHD had a trend toward reducing the risk of nonrelapse mortality (NRM) after PTCy-haplo (HR = 0.13, P = 0.060) and this positive effect was significant after CBT (HR = 0.39, P = 0.003). A negative impact of grade III-IV acute GVHD on NRM was observed after CBT and MDT, but not after PTCy-haplo. Limited chronic GVHD had a positive impact on OS after CBT and MDT, but not after PTCy-haplo. In conclusion, mild acute GVHD improved outcomes after PTCy-haplo and CBT, and limited chronic GVHD improved outcomes after CBT and MDT. These data indicated that the effects of GVHD on transplant outcomes depended on transplant platforms.

Published
2023

16. Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation

Author

Wada, Fumiya, primary, Kanda, Junya, additional, Kamijo, Kimimori, additional, Nishikubo, Masashi, additional, Yoshioka, Satoshi, additional, Ishikawa, Takayuki, additional, Ueda, Yasunori, additional, Akasaka, Takashi, additional, Arai, Yasuyuki, additional, Izumi, Kiyotaka, additional, Hirata, Hirokazu, additional, Ikeda, Takashi, additional, Yonezawa, Akihito, additional, Anzai, Naoyuki, additional, Watanabe, Mitsumasa, additional, Imada, Kazunori, additional, Yago, Kazuhiro, additional, Tamura, Naoki, additional, Itoh, Mitsuru, additional, Masuo, Yuki, additional, Kunitomi, Akane, additional, Takeoka, Tomoharu, additional, Kitano, Toshiyuki, additional, Arima, Nobuyoshi, additional, Hishizawa, Masakatsu, additional, Asagoe, Kohsuke, additional, Kondo, Tadakazu, additional, and Takaori-Kondo, Akifumi, additional

Published
2023
Full Text
View/download PDF

17. Resistance of KIR ligand-missing leukocytes to natural killer cells in vivo in patients with acquired aplastic anemia

Author

Nguyen Thi, Mai Anh, Hosokawa, Kohei, Yoroidaka, Takeshi, Maruyama, Hiroyuki, Espinoza, J. Luis, Elbadry, Mahmoud I., Md, Mohiuddin, Tanabe, Mikoto, Katagiri, Takamasa, Nakagawa, Noriharu, Arima, Nobuyoshi, Kashiwase, Koichi, Saji, Hiroh, Ogawa, Seishi, and Nakao, Shinji

Subjects
aplastic anemia, Resistance of KIR-L(-) cells to NK cells in AA, killer cell immunoglobulin-like receptor, pLOH
Abstract

金沢大学医薬保健研究域医学系 Graduate School of Medical Sciences, The loss of killer cell immunoglobulin-like receptor-ligands (KIR-Ls) due to the copy number neutral loss of heterozygosity of chromosome 6p (6pLOH) in leukocytes of patients with acquired aplastic anemia (AA) may alter the susceptibility of the affected leukocytes to NK cell killing in vivo. We studied 408 AA patients, including 261 who were heterozygous for KIR-Ls, namely C1/C2 or Bw6/Bw4, for the presence of KIR-L-missing (KIR-L[-]) leukocytes. KIR-L(-) leukocytes were found in 14 (5.4%, C1, n= 4, C2, n=3, and Bw4, n= 7) of the 261 patients, in whom corresponding KIR(+) licensed NK cells were detected. The incidence of 6pLOH in the 261 patients (18.0%) was comparable to that in 147 patients (13.6%) who were homozygous for KIR-L genes. The percentages of HLA-lacking granulocytes (0.8-50.3%, median 15.2%) in the total granulocytes of the patients with KIR-L(-) cells were significantly lower than those (1.2-99.4%, median 55.4%) in patients without KIR-L(-) cells. KIR2DS1 and KIR3DS1 were only possessed by three of the 14 patients, two of whom had C2/C2 leukocytes after losing C1 alleles. The expression of the KIR3DS1 ligand HLA-F was selectively lost on KIR-L(-) primitive hematopoietic stem cells (HSCs) derived from 6pLOH(+) iPS cells in one of the KIR3DS1(+) patients. These findings suggest that human NK cells are able to suppress the expansion of KIR-L(-) leukocytes but are unable to eliminate them partly due to the lack of activating KIRs on NK cells and the low HLA-F expression level on HSCs in AA patients., Embargo Period 6 months

Published
2020

18. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial

Author

30636311, 70217933, Muranushi, Hiroyuki, Kanda, Junya, Kobayashi, Masayuki, Maeda, Takeshi, Kitano, Toshiyuki, Tsuji, Masaaki, Ueda, Yasunori, Ishikawa, Takayuki, Nohgawa, Masaharu, Watanabe, Mitsumasa, Imada, Kazunori, Moriguchi, Toshinori, Itoh, Mitsuru, Ohno, Hitoshi, Yonezawa, Akihito, Hirata, Hirokazu, Arima, Nobuyoshi, Asagoe, Kohsuke, Anzai, Naoyuki, Nagata, Kayoko, Yasuno, Shinji, Kuwabara, Yoshihiro, Kitao, Hiromi, Kim, Ihhwa, Kawagishi, Kiyomi, Ueshima, Kenji, Tominari, Shinjiro, Nakayama, Takeo, Yamashita, Kouhei, Takaori-Kondo, Akifumi, 30636311, 70217933, Muranushi, Hiroyuki, Kanda, Junya, Kobayashi, Masayuki, Maeda, Takeshi, Kitano, Toshiyuki, Tsuji, Masaaki, Ueda, Yasunori, Ishikawa, Takayuki, Nohgawa, Masaharu, Watanabe, Mitsumasa, Imada, Kazunori, Moriguchi, Toshinori, Itoh, Mitsuru, Ohno, Hitoshi, Yonezawa, Akihito, Hirata, Hirokazu, Arima, Nobuyoshi, Asagoe, Kohsuke, Anzai, Naoyuki, Nagata, Kayoko, Yasuno, Shinji, Kuwabara, Yoshihiro, Kitao, Hiromi, Kim, Ihhwa, Kawagishi, Kiyomi, Ueshima, Kenji, Tominari, Shinjiro, Nakayama, Takeo, Yamashita, Kouhei, and Takaori-Kondo, Akifumi

Abstract

[Objectives:] We conducted a phase II trial to prospectively evaluate the efficacy and safety of bortezomib-cyclophosphamide-dexamethasone (VCD) induction, autologous stem cell transplantation (ASCT), VCD consolidation, and bortezomib maintenance in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients in Japan (UMIN000010542). [Methods:] From 2013 to 2016, 42 patients with a median age of 58 (range 42–65) years with NDMM were enrolled in 15 centers. The primary endpoint was the complete response (CR) /stringent CR (sCR) rate after transplantation, and overall/progression-free survival rates were also evaluated. [Results:] Following induction therapy, the overall response rate was obtained in 71% of patients, including a CR/sCR of 10% and a very good partial response (VGPR) of 26%. Twenty-six of the 42 patients completed ASCT following the protocol and CR/sCR and VGPR rate 100 days after ASCT was 26% and 17%, respectively. During consolidation therapy, 3 of the 24 patients achieved deeper responses. Eight of the 18 patients completed 2-year bortezomib maintenance without disease progression and grade 3/4 toxicities. Five patients were VGPR or partial response after ASCT but maintained response with 2-year bortezomib maintenance. Two-year overall and progression-free survival rates were 92.5% (95% confidence interval [CI]: 78.5%−97.5%) and 62.6% (95% CI: 45.8%−75.5%), respectively. Grade 3/4 toxicities (≥ 10%) included neutropenia (19%) and anemia (17%) in induction, and thrombocytopenia (29%) in consolidation. [Conclusion:] VCD induction/consolidation and bortezomib maintenance with ASCT for NDMM resulted in a high CR/sCR rate and provided good overall/progression-free survival in Japan.

Published
2022

19. Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies

Author

10826564, Wada, Fumiya, Kanda, Junya, Yoshioka, Satoshi, Ishikawa, Takayuki, Akasaka, Takashi, Ueda, Yasunori, Hirata, Hirokazu, Arai, Yasuyuki, Yago, Kazuhiro, Anzai, Naoyuki, Watanabe, Mitsumasa, Ikeda, Takashi, Yonezawa, Akihito, Imada, Kazunori, Itoh, Mitsuru, Kitano, Toshiyuki, Takeoka, Tomoharu, Hishizawa, Masakatsu, Nohgawa, Masaharu, Arima, Nobuyoshi, Asagoe, Kousuke, Kondo, Tadakazu, Takaori-Kondo, Akifumi, 10826564, Wada, Fumiya, Kanda, Junya, Yoshioka, Satoshi, Ishikawa, Takayuki, Akasaka, Takashi, Ueda, Yasunori, Hirata, Hirokazu, Arai, Yasuyuki, Yago, Kazuhiro, Anzai, Naoyuki, Watanabe, Mitsumasa, Ikeda, Takashi, Yonezawa, Akihito, Imada, Kazunori, Itoh, Mitsuru, Kitano, Toshiyuki, Takeoka, Tomoharu, Hishizawa, Masakatsu, Nohgawa, Masaharu, Arima, Nobuyoshi, Asagoe, Kousuke, Kondo, Tadakazu, and Takaori-Kondo, Akifumi

Abstract

[Background.] Unrelated cord blood (UCB) and haploidentical related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) have become alternative options to treat patients with hematological malignancies without a HLA-matched donor. [Methods.] We conducted a retrospective study using registry data from the Kyoto Stem Cell Transplantation Group for patients with hematological malignancies who received their first allogeneic hematopoietic cell transplantation using a single UCB unit (n = 460) or PTCy-haplo (N = 57) between 2013 and 2019. [Results.] We found that overall survival in the UCB group was comparable to that in the PTCy-haplo group (hazard ratio, 1.00; 95% confidence interval, 0.66-1.52), although neutrophil and platelet engraftment were significantly delayed. Nonrelapse mortality risk and the incidence of graft-versus-host disease in the UCB group were also comparable to those in the PTCy-haplo group. Although the relapse risk was similar between the UCB group and the PTCy-haplo group regardless of the disease risk, acute myeloid leukemia patients benefit from UCB transplant with a significantly lower relapse rate (hazard ratio, 0.38; 95% confidence interval, 0.18-0.76). [Conclusions.] UCB transplant gives outcomes comparable to PTCy-haplo transplant, and both UCB and PTCy-haplo units are suitable as alternative donor sources for patients without an HLA-matched sibling or unrelated donor.

Published
2022

20. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial

Author

Muranushi, Hiroyuki, primary, Kanda, Junya, additional, Kobayashi, Masayuki, additional, Maeda, Takeshi, additional, Kitano, Toshiyuki, additional, Tsuji, Masaaki, additional, Ueda, Yasunori, additional, Ishikawa, Takayuki, additional, Nohgawa, Masaharu, additional, Watanabe, Mitsumasa, additional, Imada, Kazunori, additional, Moriguchi, Toshinori, additional, Itoh, Mitsuru, additional, Ohno, Hitoshi, additional, Yonezawa, Akihito, additional, Hirata, Hirokazu, additional, Arima, Nobuyoshi, additional, Asagoe, Kohsuke, additional, Anzai, Naoyuki, additional, Nagata, Kayoko, additional, Yasuno, Shinji, additional, Kuwabara, Yoshihiro, additional, Kitao, Hiromi, additional, Kim, Ihhwa, additional, Kawagishi, Kiyomi, additional, Ueshima, Kenji, additional, Tominari, Shinjiro, additional, Nakayama, Takeo, additional, Yamashita, Kouhei, additional, and Takaori-Kondo, Akifumi, additional

Published
2022
Full Text
View/download PDF

21. HLA-B Leader Dimorphism Impacts on Outcomes of HLA-Matched Related/Unrelated Transplantation: Analysis of the Japanese Society for Transplantation and Cellular Therapy

Author

Kanaya, Minoru, primary, Morishima, Yasuo, additional, Arima, Nobuyoshi, additional, Hirayama, Masahiro, additional, Shiratori, Souichi, additional, Doki, Noriko, additional, Ozawa, Yukiyasu, additional, Fukuda, Takahiro, additional, Tanaka, Masatsugu, additional, Sawa, Masashi, additional, Takada, Satoru, additional, Ota, Shuichi, additional, Kawakita, Toshiro, additional, Kanda, Junya, additional, Ichinohe, Tatsuo, additional, Atsuta, Yoshiko, additional, and Morishima, Satoko, additional

Published
2021
Full Text
View/download PDF

22. Single Cord Blood Transplantation Versus HLA-Haploidentical Related Donor Transplantation Using Post-Transplant Cyclophosphamide in Patients with Hematological Malignancies

Author

Wada, Fumiya, primary, Kanda, Junya, additional, Yoshioka, Satoshi, additional, Ishikawa, Takayuki, additional, Akasaka, Takashi, additional, Ueda, Yasunori, additional, Hirata, Hirokazu, additional, Arai, Yasuyuki, additional, Yago, Kazuhiro, additional, Anzai, Naoyuki, additional, Watanabe, Mitsumasa, additional, Ikeda, Takashi, additional, Yonezawa, Akihito, additional, Imada, Kazunori, additional, Itoh, Mitsuru, additional, Kitano, Toshiyuki, additional, Takeoka, Tomoharu, additional, Hishizawa, Masakatsu, additional, Nohgawa, Masaharu, additional, Arima, Nobuyoshi, additional, Asagoe, Kosuke, additional, Kondo, Tadakazu, additional, and Takaori-Kondo, Akifumi, additional

Published
2021
Full Text
View/download PDF

23. The HLA-B Leader MM Genotype Has a Negative Impact on Outcomes in HLA-B One Antigen Mismatched and HLA-B Matched Cord Blood Transplantation without Anti-Thymocyte Globulin: Analysis of the Japanese Society for Transplantation and Cellular Therapy

Author

Kanaya, Minoru, Hashimoto, Daigo, Morishima, Yasuo, Arima, Nobuyoshi, Hirayama, Masahiro, Murata, Makoto, Uchida, Naoyuki, Tanaka, Masatsugu, Uehara, Yasufumi, Miyakoshi, Shigesaburo, Ishiwata, Kazuya, Onizuka, Makoto, Takahashi, Satoshi, Kobayashi, Hikaru, Sawa, Masashi, Kato, Koji, Ishimaru, Fumihiko, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Morishima, Satoko

Published
2023
Full Text
View/download PDF

24. Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct entity: A multicenter, retrospective analysis in Japan

Author

Takata, Katsuyoshi, Okada, Hiroyuki, Ohmiya, Naoki, Nakamura, Shotaro, Kitadai, Yasuhiko, Tari, Akira, Akamatsu, Taiji, Kawai, Hiroki, Tanaka, Shu, Araki, Hiroshi, Yoshida, Takashi, Okumura, Hirokazu, Nishisaki, Hogara, Sagawa, Tamotsu, Watanabe, Norihiko, Arima, Nobuyoshi, Takatsu, Noritaka, Nakamura, Masanao, Yanai, Shunichi, Kaya, Hiroyasu, Morito, Toshiaki, Sato, Yasuharu, Moriwaki, Hisataka, Sakamoto, Choitsu, Niwa, Yasumasa, Goto, Hidemi, Chiba, Tsutomu, Matsumoto, Takayuki, Ennishi, Daisuke, Kinoshita, Tomohiro, and Yoshino, Tadashi

Published
2011
Full Text
View/download PDF

25. Resistance of KIR Ligand–Missing Leukocytes to NK Cells In Vivo in Patients with Acquired Aplastic Anemia

Author

Nguyen, Mai Anh Thi, primary, Hosokawa, Kohei, additional, Yoroidaka, Takeshi, additional, Maruyama, Hiroyuki, additional, Espinoza, J. Luis, additional, Elbadry, Mahmoud I., additional, Mohiuddin, Md, additional, Tanabe, Mikoto, additional, Katagiri, Takamasa, additional, Nakagawa, Noriharu, additional, Chonabayashi, Kazuhisa, additional, Yoshida, Yoshinori, additional, Arima, Nobuyoshi, additional, Kashiwase, Koichi, additional, Saji, Hiroh, additional, Ogawa, Seishi, additional, and Nakao, Shinji, additional

Published
2020
Full Text
View/download PDF

26. Therapy-Related Acute Myeloid Leukemia Following Etoposide Based Chemotherapy in Germ Cell Tumor

Author

Okumura, Yoshinaga, Oae, Masashi, Shiraishi, Yusuke, Soda, Takeshi, Kanamaru, Hiroshi, and Arima, Nobuyoshi

Subjects
Germ cell tumor, 494.9, Therapy related acute myeloid leukemia, Topoisomelase II inhibitor, Etoposide
Abstract

A 27-year-old man visited our hospital with painless swelling of the left scrotum. Hematologic studies showed the following levels of lactate dehydrogenase, 3, 171 IU/l ; alpha-fetoprotein, 2.2 ng/ml ; and β- human chorionic gonadotropin, 0.4 ng/ml, and abdominal computed tomography revealed a mass of 10×8 ×4 cm in the left testis, and that of 3.5×3.0×5.0 cm in the left renal hilar lymph node, without any other metastasis. Left high inguinal orchiectomy was performed, and histopathological examination revealed mixed form with seminoma and teratoma. He was diagnosed to have a left germ cell tumor with left renal hilar lymph node metastases, pT1, N3, M0, stage II C, indicating poor prognosis with IGCCC. The patient received four cycles of chemotherapy, COMPE regimen (CDDP, VCR, MTX, PEP, VP-16 [etoposide]). After lactate dehydrogenase, alpha-fetoprotein, and β -human chorionic gonadotropin all normalized, retroperitoneal lymph node dissection was performed. Histopathological examination revealed only a mature teratoma. Two and half years later, hematologic studies showed blast transformation. Bone marrow biopsy revealed acute myeloblastic lymphoma (M2). The patient received one cycle of AraC and daunorubicin, one cycle of high dose AraC, and three cycles of AraC and mitoxantrone. After chemotherapy, he has maintained a disease-free status for 11 years. In this case, etoposide, a topoisomerase II inhibitor, was the presumed cause of therapy-related acute myeloid leukemia. After administering chemotherapeutic agents especially etoposide, it is important to check blood count periodically for a long time.

Published
2016

27. Establishment of a Predictive Model of GvHD-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation Using a Machine Learning Algorithm

Author

Kanda, Junya, primary, Arai, Yasuyuki, additional, Kondo, Tadakazu, additional, Ishikawa, Takayuki, additional, Ueda, Yasunori, additional, Imada, Kazunori, additional, Akasaka, Takashi, additional, Yonezawa, Akihito, additional, Yago, Kazuhiro, additional, Nohgawa, Masaharu, additional, Anzai, Naoyuki, additional, Moriguchi, Toshinori, additional, Kitano, Toshiyuki, additional, Itoh, Mitsuru, additional, Arima, Nobuyoshi, additional, Takeoka, Tomoharu, additional, Watanabe, Mitsumasa, additional, Hirata, Hirokazu, additional, Asagoe, Kosuke, additional, Miyanishi, Masanori, additional, Miyatsuka, Isao, additional, An, Le My, additional, and Takaori-Kondo, Akifumi, additional

Published
2019
Full Text
View/download PDF

28. Phase II Trial of Bortezomib-Based Induction, Autologous Stem Cell Transplantation, Bortezomib-Based Consolidation, and Bortezomib Maintenance in Newly Diagnosed Multiple Myeloma in Japan

Author

Kanda, Junya, primary, Kobayashi, Masayuki, additional, Maeda, Takeshi, additional, Toshiyuki, Toshiyuki, additional, Tsuji, Masaaki, additional, Ohno, Tatsuharu, additional, Ueda, Yasunori, additional, Ishikawa, Takayuki, additional, Nohgawa, Masaharu, additional, Watanabe, Mitsumasa, additional, Imada, Kazunori, additional, Moriguchi, Toshinori, additional, Itoh, Mitsuru, additional, Ohno, Hitoshi, additional, Yonezawa, Akihito, additional, Hirata, Hirokazu, additional, Arima, Nobuyoshi, additional, Asagoe, Kosuke, additional, Anzai, Naoyuki, additional, Yasuno, Shinji, additional, Kuwabara, Yoshihiro, additional, Kitao, Hiromi, additional, Kim, Ihhwa, additional, Kawagishi, Kiyomi, additional, Ueshima, Kenji, additional, Tominari, Shinjiro, additional, Nakayama, Takeo, additional, Yamashita, Kouhei, additional, and Takaori-Kondo, Akifumi, additional

Published
2018
Full Text
View/download PDF

29. Impact of Homozygous Conserved Extended HLA Haplotypes on Cord Blood Transplantation: Implications for Induced Pluripotent Stem Cell Banking and Transplantation

Author

Morishima, Yasuo, primary, Morishima, Satoko, additional, Murata, Makoto, additional, Arima, Nobuyoshi, additional, Uchida, Naoyuki, additional, Ohno, Yuji, additional, Takahashi, Satoshi, additional, Matsuhashi, Yoshiko, additional, Onizuka, Makoto, additional, Eto, Tetsuya, additional, Atsuta, Yoshiko, additional, Fukuda, Takahiro, additional, Ichinohe, Tatsuo, additional, Kato, Shunichi, additional, and Kanda, Junya, additional

Published
2018
Full Text
View/download PDF

30. Multiple Myeloma Presenting with Autoimmune Autonomic Ganglionopathy

Author

Nakae, Yoshiki, primary, Hyuga, Mizuki, additional, Terada, Yuta, additional, Kishimoto, Wataru, additional, Fukunaga, Akiko, additional, Tabata, Sumie, additional, Maesako, Yoshitomo, additional, Komatsu, Kenichi, additional, Higuchi, Osamu, additional, Nakane, Toshinari, additional, and Arima, Nobuyoshi, additional

Published
2017
Full Text
View/download PDF

32. Association of Increased Ring Ssideroblasts with Inferior Survival in Patients with Myelodysplastic Syndrome with Multi-Lineage Dysplasia

Author

Kawabata, Hiroshi, primary, Tohyama, Kaoru, additional, Matsuda, Akira, additional, Araseki, Kayano, additional, Hata, Tomoko, additional, Suzuki, Takahiro, additional, Kayano, Hidekazu, additional, Shinbo, Kei, additional, Usuki, Kensuke, additional, Hangaishi, Akira, additional, Chiba, Shigeru, additional, Masaharu, Nogawa, additional, Arima, Nobuyoshi, additional, Ishikawa, Takayuki, additional, Ozawa, Keiya, additional, Arai, Shunya, additional, Kurokawa, Mineo, additional, and Takaori-Kondo, Akifumi, additional

Published
2016
Full Text
View/download PDF

34. Clinical Significance of Natural Killer Cell-Mediated Alloreactivity in Unrelated Cord Blood Transplantation for Children with Acute Leukemia: A Japanese National Registry Study

Author

Sakaguchi, Hirotoshi, Arima, Nobuyoshi, Narita, Atsushi, Ishimaru, Sae, Tomizawa, Daisuke, Hasegawa, Daiichiro, Kato, Motohiro, Ishida, Hiroyuki, Kanda, Junya, Inoue, Masami, Yoshida, Nao, Koh, Katsuyoshi, Inagaki, Jiro, Ogawa, Atsushi, Hori, Tsukasa, Hashii, Yoshiko, Kato, Koji, and Atsuta, Yoshiko

Published
2017
Full Text
View/download PDF

36. Management Of Pregnancy In Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report Of 10 Cases From The Working Group On Pregnancy Of The Japan PNH Study Group

Author

Usuki, Kensuke, primary, Urabe, Akio, additional, Kawaguchi, Tatsuya, additional, Miyasaka, Naoyuki, additional, Miura, Osamu, additional, Morishita, Eriko, additional, Arima, Nobuyoshi, additional, Morita, Yasuyoshi, additional, Nishiwaki, Kaichi, additional, Ninomiya, Haruhiko, additional, Gotoh, Akihiko, additional, Imashuku, Shinsaku, additional, Shichishima, Tsutomu, additional, Nishimura, Jun-ichi, additional, and Kanakura, Yuzuru, additional

Published
2013
Full Text
View/download PDF

38. Short Cycle of Immunochemotherapy Followed by Radiation Therapy Compared with Prolonged Cycles of Immunochemotherapy for Localized DLBCL: The Osaka Lymphoma Study Group (OLSG) Retrospective Analysis

Author

Terada, Yoshiki, primary, Take, Hironori, additional, Shibayama, Hirohiko, additional, Hashimoto, Koji, additional, Kuwayama, Maki, additional, Fujii, Norie, additional, Azenishi, Yasuhiko, additional, Maeda, Yasuhiro, additional, Yamagami, Tamotu, additional, Uoshima, Nobuhiko, additional, Tsukaguchi, Machiko, additional, Semba, Osamu, additional, Mitui, Hideki, additional, Ueda, Shuji, additional, Soma, Toshihiro, additional, Nakagawa, Masashi, additional, Matuda, Mituhiro, additional, Urase, Fumiaki, additional, Kiyoi, Teruo, additional, Yoshida, Hitoshi, additional, Sugahara, Hiroyuki, additional, Yamashita, Kenichi, additional, Tominaga, Nobuhiko, additional, Kubota, Takeshi, additional, Arima, Nobuyoshi, additional, Mori, Shinichirou, additional, Tamaki, Toshiharu, additional, Okamoto, Takahiro, additional, Anzai, Naoyuki, additional, Akasaka, Hiroshi, additional, Tabata, Rie, additional, Ikeda, Junichiro, additional, Wada, Naoki, additional, Aozasa, Katsuyuki, additional, and Hino, Masayuki, additional

Published
2012
Full Text
View/download PDF

41. Establishment of a Predictive Model for GvHD-free, Relapse-free Survival after Allogeneic HSCT using Ensemble Learning

Author

Iwasaki, Makoto, Kanda, Junya, Arai, Yasuyuki, Kondo, Tadakazu, Ishikawa, Takayuki, Ueda, Yasunori, Imada, Kazunori, Akasaka, Takashi, Yonezawa, Akihito, Yago, Kazuhiro, Nohgawa, Masaharu, Anzai, Naoyuki, Moriguchi, Toshinori, Kitano, Toshiyuki, Itoh, Mitsuru, Arima, Nobuyoshi, Takeoka, Tomoharu, Watanabe, Mitsumasa, Hirata, Hirokazu, Asagoe, Kosuke, Miyatsuka, Isao, An, Le My, Miyanishi, Masanori, and Takaori-Kondo, Akifumi

Abstract

Graft-versus-host-disease-free, relapse-free survival (GRFS) is a useful composite endpoint that measures survival without relapse or significant morbidity after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to develop a novel analytical method that appropriately handles right-censored data and competing risks to understand the risk for GRFS and each component of GRFS.This study was a retrospective data-mining study on a cohort of 2207 adult patients who underwent their first allo-HSCT at the Kyoto Stem Cell Transplantation Group (KSCTG), a multi-institutional joint research group of 17 transplantation centers in Japan. The primary endpoint was GRFS. A stacked ensemble of Cox proportional hazard regression and seven machine learning algorithms was applied to develop a prediction model.The median age of patients was 48 years. For GRFS, the stacked ensemble model achieved better predictive accuracy evaluated by C-index than other top-of-the-art competing risk models (ensemble model: 0.670, Cox-PH: 0.668, Random Survival Forest: 0.660, Dynamic DeepHit: 0.646). The probability of GRFS after 2 years was 30.54% for the high-risk and 40.69% for the low-risk group, respectively (hazard ratio [HR] compared to the low-risk group: 2.127; 95% CI: 1.19-3.80).We developed a novel predictive model for survival analysis that showed superior risk stratification to existing methods using a stacked ensemble of multiple machine learning algorithms.

Published
2021
Full Text
View/download PDF

42. Pathogenic TNFRSF13B Variant in an Adult Japanese Patient with Common Variable Immunodeficiency.

Author

Nakamura N, Ikunari R, Tanaka Y, Tsunemine H, Takeda J, and Arima N

Abstract

Common variable immunodeficiency (CVID) is a primary B cell immunodeficiency disorder. Symptoms do not develop immediately after birth, and patients are often diagnosed in childhood and adulthood. These patients often develop autoimmune diseases and malignant tumors. We herein report a 50-year-old woman with severe hypogammaglobulinemia and recurrent respiratory tract infections who was diagnosed with CVID. Target sequencing showed a TNFRSF13B heterozygous frameshift variant. The patient had many comorbidities, probably caused by a CVID-induced immune imbalance. Physicians who treat adult patients are often unaware of CVID. CVID should be recognized as a differential diagnosis in hypogammaglobulinemia and recurrent infections.

Published
2024
Full Text
View/download PDF

43. Red blood cell distribution width is a useful biomarker to predict bleeding and thrombosis risks in patients with immune thrombocytopenic purpura.

Author

Nakamura N, Tsunemine H, Ikunari R, Tanaka Y, and Arima N

Abstract

Bleeding and thrombosis are common complications during immune thrombocytopenic purpura (ITP) treatment. There is a strong need to predict bleeding and thrombosis risks before ITP treatment to optimize therapy and appropriately manage these complications. We performed a retrospective cohort study of 120 patients with primary ITP to identify a biomarker to predict bleeding and thrombosis. We compared blood test results at diagnosis between patients with and without bleeding or thrombosis episodes. The standard deviation of red blood cell distribution width (RDW-SD) differed significantly between those with and without bleeding and between those with and without thrombosis, leading us to identify it as a variable representative of risk. RDW-SD was significantly associated with patient age and with histories of several vascular diseases. Multivariate regression analyses showed that RDW integrated several variables associated with vascular risks. RDW-SD was significantly associated with difficulty with corticosteroid discontinuation (hazard ratio [HR], 2.22, p  = 0.01), incidence of bleeding (HR, 2.75, p < 0.01), incidence of thrombosis (HR, 2.67, p < 0.01) and incidence of infection (HR, 1.78, p  = 0.04). The RDW-SD value at the time of ITP diagnosis is a useful biomarker to predict the risks of bleeding, thrombosis, and other complications., Competing Interests: The authors declare no conflicts of interests., (© 2024 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

44. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders presented as interstitial pneumonia; successful recovery with rituximab.

Author

Kunitomi A, Arima N, and Ishikawa T

Subjects
Antibodies, Monoclonal, Murine-Derived, Diagnosis, Differential, Epstein-Barr Virus Infections diagnosis, Epstein-Barr Virus Infections etiology, Herpesvirus 4, Human, Humans, Lung Diseases, Interstitial diagnosis, Lung Diseases, Interstitial etiology, Lymphoproliferative Disorders diagnosis, Lymphoproliferative Disorders etiology, Male, Middle Aged, Postoperative Complications diagnosis, Postoperative Complications drug therapy, Rituximab, Antibodies, Monoclonal therapeutic use, Bone Marrow Transplantation adverse effects, Epstein-Barr Virus Infections drug therapy, Lung Diseases, Interstitial drug therapy, Lymphoproliferative Disorders drug therapy
Abstract

We describe a patient that developed Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorders (PTLD), which presented as interstitial pneumonia. He had received allogeneic bone marrow transplantation for the treatment of acute myeloid leukemia 17 months before, when he developed hypoxemia requiring emergent admission. Chest computed tomography revealed pulmonary interstitial shadows, but neither hepatomegaly nor lymphadenopathy were detected. Bronchoscopy with lung biopsy revealed a lymphomatous proliferation of EBV-infected B cells. The interstitial pneumonia rapidly deteriorated, but improved dramatically after treatment with anti-CD20 monoclonal antibody (rituximab). This is the first report of a patient with lung EBV-PTLD that presented as interstitial pneumonia and was successfully treated with rituximab.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results